ArticlePharmacology, biochemistry, and behavior2010
Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain.
Article in Pharmacology, biochemistry, and behavior, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Non-Pulmonary Mechanisms of Action of Ambroxol in In Vivo Experimental Models: a Systematic Review.Fundamental & clinical pharmacology · 2026Pooled it
- Therapeutic Potential of Ambroxol in Osteoarthritis: A Drug Repurposing Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Analgesic and Anti-Inflammatory Activity of Ambroxol in the Treatment of Endometriosis: An Experimental Study in Wistar Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Refinement of the motorised laminectomy-assisted rat spinal cord injury model by analgesic treatment.PloS one · 2024Article
- Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain.Pharmaceutics · 2023Review
- Intrathecal administration of naringenin improves motor dysfunction and neuropathic pain following compression spinal cord injury in rats: relevance to its antioxidant and anti-inflammatory activities.The Korean journal of pain · 2022Article
- The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice.Molecules (Basel, Switzerland) · 2021Article
- A novel P2X2-dependent purinergic mechanism of enteric gliosis in intestinal inflammation.EMBO molecular medicine · 2021Article
- Status of peripheral sodium channel blockers for non-addictive pain treatment.Nature reviews. Neurology · 2020Review
- Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs.Molecular psychiatry · 2020Article
- Sex Difference in Trigeminal Neuropathic Pain Response to Exercise: Role of Oxidative Stress.Pain research & management · 2020Article
- Article
- Uroprotective effect of ambroxol in cyclophosphamide-induced cystitis in mice.International urology and nephrology · 2019Article
- Experimental Drugs for Neuropathic Pain.Current neuropharmacology · 2018Review
- Ambroxol for fibromyalgia: one group pretest-posttest open-label pilot study.Clinical rheumatology · 2017Article
- Topical Treatments for Localized Neuropathic Pain.Current pain and headache reports · 2017Review
- Ambroxol for the treatment of fibromyalgia: science or fiction?Journal of pain research · 2017Article
- [Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version].Schmerz (Berlin, Germany) · 2015Article
- Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation.Schmerz (Berlin, Germany) · 2015Observational
- Functional up-regulation of Nav1.8 sodium channel in Aβ afferent fibers subjected to chronic peripheral inflammation.Journal of neuroinflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Symptoms of neuropathic spinal cord injury (SCI) pain include evoked cutaneous hypersensitivity and spontaneous pain, which can be present below the level of the injury. Adverse side-effects obtained with currently available analgesics complicate effective pain management in SCI patients. Voltage-gated Na(+) channels expressed in primary afferent nociceptors have been identified to mediate persistent hyperexcitability in dorsal root ganglia (DRG) neurons, which in part underlies the symptoms of nerve injury-induced pain. Ambroxol has previously demonstrated antinociceptive effects in rat chronic pain models and has also shown to potently block Na(+) channel current in DRG neurons. Ambroxol was tested in rats that underwent a mid-thoracic spinal cord compression injury. Injured rats demonstrated robust hind paw (below-level) heat and mechanical hypersensitivity. Orally administered ambroxol significantly attenuated below-level hypersensitivity at doses that did not affect performance on the rotarod test. Intrathecal injection of ambroxol did not ameliorate below-level hypersensitivity. The current data suggest that ambroxol could be effective for clinical neuropathic SCI pain. Furthermore, the data suggest that peripherally expressed Na(+) channels could lend themselves as targets for the development of pharmacotherapies for SCI pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.